Poolbeg Pharma trial continues after interim safety review

London - Poolbeg Pharma has confirmed its TOPICAL clinical trial will continue as initially scheduled, following a positive safety assessment, according to a news release. The trial is assessing POLB 001 as a preventive measure for Cytokine Release Syndrome in patients with relapsed or refractory multiple myeloma who are receiving the bispecific antibody teclistamab.

The interim review concluded that no adjustments to the study protocol were required. Poolbeg Pharma is actively recruiting patients at clinical sites in the UK, with more participants anticipated and additional sites set to join the trial. Chief Executive Officer Jeremy Skillington highlighted the interim cohort's data as a significant milestone for the TOPICAL trial.

The company's confidence in advancing the POLB 001 program has been bolstered by the positive interim review recommendation. Poolbeg Pharma, a clinical-stage biopharmaceutical company, is focused on cancer immunotherapy, alongside the development of an oral GLP-1 therapy for obesity. The company recently hosted an analyst and investor presentation on the Investor Meet Company platform. This report is AI-generated and reviewed by an editor.